{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:21Z","timestamp":1791825321411,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12-HD000850"],"award-info":[{"award-number":["K12-HD000850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI124316-01"],"award-info":[{"award-number":["U01-AI124316-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U54-HD090259"],"award-info":[{"award-number":["U54-HD090259"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cefazolin and ertapenem combination therapy was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (\u226424 hours) in 8 cases. While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of MSSA endocarditis. The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacteremia and endocarditis.<\/jats:p>","DOI":"10.1093\/cid\/ciz995","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T11:07:14Z","timestamp":1571569634000},"page":"1413-1418","source":"Crossref","is-referenced-by-count":55,"title":["Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia"],"prefix":"10.1093","volume":"71","author":[{"given":"Erlinda R","family":"Ulloa","sequence":"first","affiliation":[{"name":"Collaborative to Halt Antibiotic-Resistant Microbes, Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA"},{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindra V","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Center for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[{"name":"Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Haddad","sequence":"additional","affiliation":[{"name":"Sharp Grossmont Hospital, La Mesa, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Center for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nizet","sequence":"additional","affiliation":[{"name":"Collaborative to Halt Antibiotic-Resistant Microbes, Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA"},{"name":"Skaggs School of Pharmacy, University of California, San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Collaborative to Halt Antibiotic-Resistant Microbes, Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA"},{"name":"Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"2020091210442754100_CIT0001","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"2020091210442754100_CIT0002","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020091210442754100_CIT0003","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"2020091210442754100_CIT0004","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/379021","article-title":"Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue","volume":"37","author":"Nannini","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020091210442754100_CIT0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.1977.03270330059022","article-title":"Unsuccessful treatment of staphylococcal endocarditis with cefazolin","volume":"237","author":"Bryant","year":"1977","journal-title":"JAMA"},{"key":"2020091210442754100_CIT0006","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1093\/infdis\/128.Supplement_2.S386","article-title":"Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis","volume":"128","author":"Quinn","year":"1973","journal-title":"J Infect Dis"},{"key":"2020091210442754100_CIT0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/430833","article-title":"Cefazolin therapy for Staphylococcus aureus bacteremia","volume":"41","author":"Fernandez-Guerrero","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020091210442754100_CIT0008","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/AAC.01192-16","article-title":"Cefazolin and ertapenem, a synergistic combination used to clear persistent Staphylococcus aureus bacteremia","volume":"60","author":"Sakoulas","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0009","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2016","edition":"26"},{"key":"2020091210442754100_CIT0010","volume-title":"Tests to assess bactericidal activity, in clinical microbiology procedures handbook","author":"Moody","year":"2010"},{"key":"2020091210442754100_CIT0011","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1128\/AAC.00856-13","article-title":"In vivo effects of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin","volume":"57","author":"Nannini","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00324-17","article-title":"Efficacy of ceftaroline against methicillin-susceptible Staphylococcus aureus exhibiting the cefazolin high-inoculum effect in a rat model of endocarditis","volume":"61","author":"Singh","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0013","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","article-title":"Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens","volume":"2","author":"Lin","year":"2015","journal-title":"EBioMedicine"},{"key":"2020091210442754100_CIT0014","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jac\/dkv487","article-title":"Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia","volume":"71","author":"Kumaraswamy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020091210442754100_CIT0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.05.026","article-title":"Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing","volume":"20","author":"Ersoy","year":"2017","journal-title":"EBioMedicine"},{"key":"2020091210442754100_CIT0016","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? A review of antimicrobial synergy testing","volume":"52","author":"Doern","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020091210442754100_CIT0017","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0018","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020091210442754100_CIT0019","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2020091210442754100_CIT0020","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00382-18","article-title":"Prevalence of a cefazolin inoculum effect associated with blaZ gene types among methicillin-susceptible Staphylococcus aureus isolates from four major medical centers in Chicago","volume":"62","author":"Wang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0022","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","article-title":"Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome","volume":"34","author":"Chong","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020091210442754100_CIT0023","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/jac\/dkt254","article-title":"Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals","volume":"68","author":"Rinc\u00f3n","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020091210442754100_CIT0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10096-018-3392-6","article-title":"Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics","volume":"38","author":"Song","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020091210442754100_CIT0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/infdis\/161.6.1170","article-title":"Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus","volume":"161","author":"Chambers","year":"1990","journal-title":"J Infect Dis"},{"key":"2020091210442754100_CIT0026","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1128\/AAC.01401-10","article-title":"Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus","volume":"55","author":"Dumitrescu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0027","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/AAC.46.9.2878-2884.2002","article-title":"Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses","volume":"46","author":"Bamberger","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020091210442754100_CIT0028","doi-asserted-by":"crossref","first-page":"O1075","DOI":"10.1111\/1469-0691.12756","article-title":"Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone","volume":"20","author":"Pericas","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz995\/31142846\/ciz995.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/6\/1413\/33738729\/ciz995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/6\/1413\/33738729\/ciz995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T14:45:41Z","timestamp":1599921941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/6\/1413\/5644098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,11,27]]},"published-print":{"date-parts":[[2020,9,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz995","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,15]]},"published":{"date-parts":[[2019,11,27]]}}}